Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial | 5 |
Aylık toplam ziyaret
| views | |
|---|---|
| Kasım 2024 | 0 |
| Aralık 2024 | 0 |
| Ocak 2025 | 1 |
| Şubat 2025 | 0 |
| Mart 2025 | 0 |
| Nisan 2025 | 0 |
| Mayıs 2025 | 4 |
Dosya Ziyaretleri
| views | |
|---|---|
| camidge-et-al-2024-telisotuzumab-vedotin-monotherapy-in-patients-with-previously-treated-c-met-protein-overexpressing.pdf | 14 |
